The EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy and then as monotherapy,  to treat select patients with follicular lymphoma. The recommendation is as treatment for ... Read more